

AAAAAAAAAGGUUUUCAUGCGUGCUCACAGAU CAGCUCUUUCUGG
AUUGAAAAGCUAAGCACAGAACAU GGGAAAAUCCUUUCAUAUGGCUG
UGUUUACAAACAAAAAGUAUAAACAUCUUGAGCAAACAGAAAUGGUGA
GGAAAACUUUGUUAGCAGAUUAG [SEQ ID NO:3]

or

(a2) ARNA VI

Klon-P10 (ARNA VI)

UUACAGCUCUUCUGUUUAUAAGUUUAUCAAUACCAAAUUAGUAG
UUUGUAUGUUUAUAAAUUUGUAGGAAAAUAAUUAUAUAUGCUUACUUU
GUACAUAAAAAUAAAAACAUGACUUCUUUAGACACUCCUUCAUUAGAA
AUAAAAUAAAAUAAACUAUUAGCAGUUUGACUUCAUGUUCUGUCUGUA
GGUCAUGGAAUCCUGUCCUUAACAAUAUUUAUUGAUUGUGAAAAUAUCA
GUAAAUAAGCAAUUGAAUAUGUUUACCUUUUCUUCUAGUCACUAUGUU
CUUAGAGUUAUGACA [SEQ ID NO:4]

9. A process for producing a metal-containing ribonucleotide protein (RPN) according to claim 1, characterized in that leucocytes or inflammation tissue is homogenized or leucocytes are cultivated and the resulting RNP is recovered from the homogenates or from the supernatant of the culture solution by standard methods.

10. A use of the metal-containing ribonucleotide protein (RPN) according to claim 1 and/or molecular-biological equivalent structures and/or fragments and/or derivatives for producing a medicament for specifically influencing angiogenesis.

REMARKS

The Present Invention

The present invention is directed to metal containing ribonucleotide polypeptides (RNPs) (claim 12), and a process (claim 13) and use (Claim 14) thereof.